keyword
MENU ▼
Read by QxMD icon Read
search

antipsychotic switching

keyword
https://www.readbyqxmd.com/read/29045304/effect-of-clozapine-vs-other-second-generation-antipsychotics-on-hospitalization-and-seclusion-a-retrospective-mirror-image-study-in-a-japanese-public-psychiatric-hospital
#1
Fuminari Misawa, Takefumi Suzuki, Yasuo Fujii
BACKGROUND: Clozapine has been regarded as the gold standard for patients with treatment-resistant schizophrenia, but a recent network meta-analysis has questioned its relative superiority over other second-generation antipsychotics (SGAs) such as olanzapine and risperidone. PURPOSE: We conducted a retrospective mirror-image study of clozapine vs other SGAs to evaluate real-world effectiveness of clozapine in terms of the duration of hospitalization and seclusion, both of which represent a critical outcome...
October 17, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29018549/perceptions-and-knowledge-of-antipsychotics-among-mental-health-professionals-and-patients
#2
Lindah Cahling, Anders Berntsson, Gabriella Bröms, Lars Öhrmalm
Aims and method To assess the patients' most influential concerns regarding long-acting injectable antipsychotics (LAIs) and mental health professionals' preconceptions about these concerns. For both groups, to assess the level of knowledge about LAIs. This cross-sectional study used semi-structured interviews of patients with schizophrenia or schizoaffective disorder (n = 164), nurses (n = 43) and physicians (n = 20). Results The mental health professionals overestimated many of the patients' fears of LAIs, and the expressed fears exceeded the actual experiences of patients already on LAIs...
October 2017: BJPsych Bulletin
https://www.readbyqxmd.com/read/28962597/periodic-catatonia-with-long-term-treatment-a-case-report
#3
Ruei-An Chen, Tiao-Lai Huang
BACKGROUND: Periodic catatonia has long been a challenging diagnosis and there are no absolute guidelines for treatment when precipitating factors are also unclear. We report a schizophrenia patient with periodic catatonia with a 15-year treatment course. A possible correlation between decreased daylight exposure and periodic attacks has been observed. CASE PRESENTATION: We describe a 49-year-old woman with periodic catatonia associated with schizophrenia with 15 years of follow-up...
September 29, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28953799/assessing-the-critical-issues-of-atypical-antipsychotics-in-schizophrenic-inpatients
#4
Francesco Franza, Barbara Solomita, Gino Aldi, Gianfranco Del Buono
Antipsychotics are effective in reducing positive and disorganization symptoms of schizophrenia. Although SGAs initially all were believed to be more efficacious and tolerable than FGAs, several data show that the SGAs are no more effective than FGAs. In clinical practice, frequent switching of antipsychotic medications is widespread for lack of efficacy, adverse side effects, and partial or not-compliance response. This study suggested that most clinically stable inpatients with schizophrenia maintain their remission states after being switched to another atypical antipsychotic; but that at the end (after 20 years) of the observation period of our study, 11...
September 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28927482/treating-depressive-episodes-or-symptoms-in-patients-with-schizophrenia
#5
Geeske van Rooijen, Jentien Marloes Vermeulen, Henricus Gerardus Ruhé, Lieuwe de Haan
Depressive episodes or symptoms occur frequently in patients with schizophrenia and may have far-reaching consequences. Despite the high prevalence rate and clinical relevance of this comorbidity, knowledge about treatment options is still limited. The aim of this review is to provide an overview of the literature concerning treatment options for depressive episodes or symptoms in schizophrenia. Based on the current evidence, we present a stepwise treatment approach. The first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider lowering the dosage, since increased blockade of the dopamine D2 receptors may be associated with a worse subjective sense of well-being and dysphoria...
September 20, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28889207/antipsychotic-induced-hyperprolactinemia-synthesis-of-world-wide-guidelines-and-integrated-recommendations-for-assessment-management-and-future-research
#6
REVIEW
Jasmin Grigg, Roisin Worsley, Caroline Thew, Caroline Gurvich, Natalie Thomas, Jayashri Kulkarni
RATIONALE: Hyperprolactinemia is a highly prevalent adverse effect of many antipsychotic agents, with potentially serious health consequences. Several guidelines have been developed for the management of this condition; yet, their concordance has not been evaluated. OBJECTIVES: The objectives of this paper were (1) to review current clinical guidelines; (2) to review key systematic evidence for management; and (3) based on our findings, to develop an integrated management recommendation specific to male and female patients who are otherwise clinically stabilised on antipsychotics...
September 9, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28883731/antipsychotic-associated-weight-gain-management-strategies-and-impact-on-treatment-adherence
#7
REVIEW
Madhubhashinee Dayabandara, Raveen Hanwella, Suhashini Ratnatunga, Sudarshi Seneviratne, Chathurie Suraweera, Varuni A de Silva
Antipsychotic-induced weight gain is a major management problem for clinicians. It has been shown that weight gain and obesity lead to increased cardiovascular and cerebrovascular morbidity and mortality, reduced quality of life and poor drug compliance. This narrative review discusses the propensity of various antipsychotics to cause weight gain, the pharmacologic and nonpharmacologic interventions available to counteract this effect and its impact on adherence. Most antipsychotics cause weight gain. The risk appears to be highest with olanzapine and clozapine...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28859580/simulated-effects-of-policies-to-reduce-diabetes-risk-among-adults-with-schizophrenia-receiving-antipsychotics
#8
Andrew W Mulcahy, Sharon-Lise Normand, John W Newcomer, Benjamin Colaiaco, Julie M Donohue, Judith R Lave, Emmett Keeler, Mark J Sorbero, Marcela Horvitz-Lennon
OBJECTIVE: Second-generation antipsychotics increase the risk of diabetes and other metabolic conditions among individuals with schizophrenia. Although metabolic testing is recommended to reduce this risk, low testing rates have prompted concerns about negative health consequences and downstream medical costs. This study simulated the effect of increasing metabolic testing rates on ten-year prevalence rates of prediabetes and diabetes (diabetes conditions) and their associated health care costs...
September 1, 2017: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/28844639/rapid-vs-slow-antipsychotic-initiation-in-schizophrenia-a-systematic-review-and-meta-analysis
#9
Hiroyoshi Takeuchi, Sadhana Thiyanavadivel, Ofer Agid, Gary Remington
BACKGROUND: How antipsychotics should be initiated/titrated in patients with acute schizophrenia as well as patients undergoing an antipsychotic switch remains a question. METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched. Randomized controlled trials examining rapid vs. slow antipsychotic initiation in patients with schizophrenia were selected. Data on study discontinuation, psychopathology, extrapyramidal symptoms (EPS), and treatment-emergent adverse events (TEAEs) were extracted and synthesized in studies including clinically different populations of acute patients and stable patients undergoing an antipsychotic switch...
August 22, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28812541/systematic-review-of-interventions-for-treating-or-preventing-antipsychotic-induced-tardive-dyskinesia
#10
Hanna Bergman, Dawn-Marie Walker, Adriani Nikolakopoulou, Karla Soares-Weiser, Clive E Adams
BACKGROUND: Antipsychotic medication can cause tardive dyskinesia (TD) - late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in > 20% of adults taking antipsychotic medication (first-generation antipsychotics for > 3 months), with this proportion increasing by 5% per year among those who continue to use these drugs. The incidence of TD among those taking newer antipsychotics is not different from the rate in people who have used older-generation drugs in moderate doses...
August 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28806390/combination-antipsychotic-therapies-an-analysis-from-a-longitudinal-pragmatic-trial
#11
Adriana Foster, Peter Buckley, John Lauriello, Stephen Looney, Nina Schooler
BACKGROUND: Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluating Efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (LAI) risperidone or second-generation oral antipsychotic (OA)...
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28799787/increased-risk-of-diabetes-among-6-24-year-olds-using-second-generation-antipsychotics
#12
Shan Xing, Todd A Lee
OBJECTIVES: The goal of this study was to estimate the association between use of second generation antipsychotics (SGAs) and type 2 diabetes (T2DM) among commercially insured children and young adults 6-24 years compared to users of non-SGA psychotropic medications. METHODS: Using the Truven MarketScan Commercial Claims and Encounters Database, new users of SGA and non-SGA psychotropic medications (anxiolytics, antidepressants, hypnotics, and mood stabilizers) between July 1, 2009 and December 31, 2013 who were 6-24 years of age and had continuous coverage ≥180 days before their index date (i...
August 11, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28793283/trifluoperazine-induced-suicidal-erythrocyte-death-and-s-nitrosylation-inhibition-reversed-by-the-nitric-oxide-donor-sodium-nitroprusside
#13
Mehrdad Ghashghaeinia, Mauro Carlos Wesseling, Elena Ramos, Polina Petkova-Kirova, Sabrina Waibel, Elisabeth Lang, Rosi Bissinger, Kossai Alzoubi, Baerbel Edelmann, Zohreh Hosseinzadeh, Peter Dreischer, Azam Shahvaroughi-Farahani, Ulrich Mrowietz, Martin Köberle, Lars Kaestner, Ingolf Bernhardt, Antonio Martínez-Ruiz, Thomas Wieder, Florian Lang
BACKGROUND AND PURPOSE: The high potency antipsychotic drug trifluoperazine (10-[3-(4-methyl-1-piperazinyl)-propyl]-2-(trifluoromethyl)-(10)H-phenothiazine dihydrochloride; TFP) may either counteract or promote suicidal cell death or apoptosis. Similar to apoptosis, erythrocytes may enter eryptosis, characterized by phosphatidylserine exposure at the cell surface and cell shrinkage. Eryptosis can be stimulated by an increase in cytoplasmic Ca2+ concentration ([Ca2+]i) and inhibited by nitric oxide (NO)...
2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28783939/galactorrhea-probably-related-with-switching-from-osmotic-release-oral-system-methylphenidate-mph-to-modified-release-mph-an-adolescent-case
#14
Ozalp Ekinci, Serkan Gunes, Nuran Ekinci
Galactorrhea, as an adverse effect of psychotropic medications, usually develops due to high dose of antipsychotics. Selective serotonin reuptake inhibitors (SSRIs) have also been reported to be related to galactorrhea. To the best of our knowledge, no previous study reported galactorrhea with methylphenidate (MPH) use. Hereby, we report a case of an adolescent girl who developed galactorrhea after increasing his modifed-release oral MPH to 50 mg/day while under treatment of sertraline and very low dose haloperidol...
August 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28751663/caregiver-burden-in-schizophrenia-following-paliperidone-palmitate-long-acting-injectables-treatment-pooled-analysis-of-two-double-blind-randomized-phase-three-studies
#15
Srihari Gopal, Haiyan Xu, Kelly McQuarrie, Adam Savitz, Isaac Nuamah, Kimberly Woodruff, Maju Mathews
The pooled analysis of two double-blind, randomized, multicenter, phase-3 studies evaluated predictors of improvement or worsening of schizophrenia-related caregiver burden following paliperidone palmitate long-acting injectables (1-monthly [PP1M] and 3-monthly [PP3M]) treatment. Caregivers were offered to complete the involvement evaluation questionnaire (involvement evaluation questionnaire; 31-item scale). Total, 1498 caregivers (intent-to-treat open-label analysis set, n = 1497; mean [SD] age: 51.5 [13...
July 27, 2017: NPJ Schizophrenia
https://www.readbyqxmd.com/read/28749091/efficacy-of-ziprasidone-augmentation-of-escitalopram-for-cognitive-symptoms-of-major-depressive-disorder
#16
Nadia Iovieno, Richard C Shelton, Samuel R Petrie, Cristina Cusin, Maurizio Fava, George I Papakostas
OBJECTIVE: To examine the efficacy of adjunctive ziprasidone for cognitive symptoms in adult patients with major depressive disorder (MDD) experiencing persistent symptoms after 8 weeks of open-label escitalopram. METHODS: This post hoc analysis was conducted on a database derived from a previously published study. The parent study was a multicenter, parallel, randomized, double-blind, placebo-controlled trial conducted at 3 academic medical centers in the United States from July 2008 to October 2013...
July 25, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28740637/antipsychotic-induced-hyperprolactinemia-in-tourette-syndrome
#17
REVIEW
Judith J G Rath, Marlies E J Deen, Hessel van Houten, Sebastiaan F T M de Bruijn, Joop van Gerven, Dick Mul
For many years, Tourette syndrome (TS) was considered to be a rare disorder, but tics and TS are now recognized as fairly common childhood-onset conditions. Children and adolescents with TS are frequently treated with antipsychotics, either as monotherapy or in combination with psychostimulants, melatonin and selective serotonin reuptake inhibitors (SSRIs). Antipsychotics are most often used in schizophrenia and related psychotic disorders, and in these conditions hyperprolactinemia is one of the most common adverse effects associated with antipsychotics, occurring in 40-50% of patients...
July 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28727483/pharmacological-treatment-of-tardive-dyskinesia-recent-developments
#18
Stanley N Caroff, E Cabrina Campbell, Benjamin Carroll
Tardive dyskinesia (TD) occurs in patients receiving antipsychotic treatment with dopamine receptor antagonists. Despite the prevalence of TD and its negative impact on patients' lives, there has been a lack of approved treatments and limited evidence from controlled trials of pharmacological treatment. Areas covered: PubMed was searched for English-language papers published during 2007-2016 using terms 'tardive dyskinesia' or 'drug-induced movement disorder', and 'treatment'. Studies evaluating pharmacological agents for the treatment of TD were selected...
September 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28697253/effect-of-antidepressant-switching-vs-augmentation-on-remission-among-patients-with-major-depressive-disorder-unresponsive-to-antidepressant-treatment-the-vast-d-randomized-clinical-trial
#19
RANDOMIZED CONTROLLED TRIAL
Somaia Mohamed, Gary R Johnson, Peijun Chen, Paul B Hicks, Lori L Davis, Jean Yoon, Theresa C Gleason, Julia E Vertrees, Kimberly Weingart, Ilanit Tal, Alexandra Scrymgeour, David D Lawrence, Beata Planeta, Michael E Thase, Grant D Huang, Sidney Zisook, Sanjai D Rao, Patricia D Pilkinton, James A Wilcox, Ali Iranmanesh, Mamta Sapra, George Jurjus, James P Michalets, Muhammed Aslam, Thomas Beresford, Keith D Anderson, Ronald Fernando, Sriram Ramaswamy, John Kasckow, Joseph Westermeyer, Gihyun Yoon, D Cyril D'Souza, Gunnar Larson, William G Anderson, Mary Klatt, Ayman Fareed, Shabnam I Thompson, Carlos J Carrera, Solomon S Williams, Timothy M Juergens, Lawrence J Albers, Clifford S Nasdahl, Gerardo Villarreal, Julia L Winston, Cristobal A Nogues, K Ryan Connolly, Andre Tapp, Kari A Jones, Gauri Khatkhate, Sheetal Marri, Trisha Suppes, Joseph LaMotte, Robin Hurley, Aimee R Mayeda, Alexander B Niculescu, Bernard A Fischer, David J Loreck, Nicholas Rosenlicht, Steven Lieske, Mitchell S Finkel, John T Little
Importance: Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant. Objective: To determine the relative effectiveness and safety of 3 common alternate treatments for MDD. Design, Setting, and Participants: From December 2012 to May 2015, 1522 patients at 35 US Veterans Health Administration medical centers who were diagnosed with nonpsychotic MDD, unresponsive to at least 1 antidepressant course meeting minimal standards for treatment dose and duration, participated in the study...
July 11, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28694630/mood-disorder-as-an-early-presentation-of-epidermoid-of-quadrigeminal-cistern
#20
Sujita Kumar Kar, Kuntal Kanti Das, Awadhesh Kumar Jaiswal, Sushila Jaiswal
Intracranial epidermoids are space-occupying lesions of rare variant. Although cerebropontine angle and parasellar region are common sites of occurrence, it has been reported in various other parts of the intracranial cavity. Headache and features of increased intracranial tension are the common clinical manifestation. Report of psychiatric symptoms as the initial presentation of epidermoid is not known in literature except a single case report, which describes mutism to be the manifestation of intracranial epidermoid...
July 2017: Journal of Neurosciences in Rural Practice
keyword
keyword
88298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"